Association Between Inflammatory Biomarkers and LV Function in Patients With CVD

Study Overview
=================
Brief Summary
-----------------
The association of novel inflammatory biomarkers with cardiovascular diseases is still obscure. The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission. Methods: We enrolled a total of 120 patients with HF, asymptomatic CAD and 60 healthy controls (HC) without cardiovascular diseases.

Detailed Description
-----------------
The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission. We enrolled a total of 60 patients with HF, 60 asymptomatic CAD patients and 60 healthy controls (HC) without cardiovascular diseases. Group I: 60 Healthy Subjects. Group II: 60 Patients with Stable Angina (asymptomatic CAD). Group III: 60 Patients with Heart Failure. Clinical parameters, glycemic and lipid profile, vaspin, visfatin, high-sensitivity C-reactive protein, sortilin, homocysteine, troponin I, fetuin A and lipoprotein A levels were assayed. Patients will be followed up to assess all-cause 30- and -90 day of hospital readmission.

Official Title
-----------------
Prognostic Significance of Inflammatory Biomarkers and LV Functionin Patients With Coronary Heart Disease and Heart Failure.

Conditions
-----------------
Stable Angina, Heart Failure

Intervention / Treatment
-----------------
* Other: Group I
* Other: Group II
* Other: Group III


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Either sex, aged 18 years or older. new-onset AHF or acute decompensation of chronic HF, CAD (including previous myocardial infarction, previous percutaneous or surgical coronary revascularization, or angiographic evidence that one or more major coronary arteries had narrowed by 50% or more). Exclusion Criteria: severe liver/ kidney dysfunction; severe systemic disease (such as the diseases of respiratory system/ digestive system/ nervous system etc.); malignant tumor; acute/ chronic infectious diseases; autoimmune disease or connective tissue disease; major trauma or surgical operation over the past three months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group I<br>60 Healthy Subjects. | Other: Group I<br>* Healthy Subjects<br>|
| Group II<br>60 Patients with Stable Angina. | Other: Group II<br>* Stable Angina Patients<br>|
| Group III<br>60 Patients with Heart Failure. | Other: Group III<br>* Heart Failure Patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All Cause 30 day hosptial admission | Number of patients admited to hospital during 1 month. | 1 month | 
| All Cause 90 day hosptial admission | Number of patients admited to hospital during 3 month. | 3 months | 
| vaspin (ng/ml) | vaspin blood concentration | 1 month | 
| visfatin (ng/ml) | visfatin blood concentration | 1 month | 
| Sortillin (pg/ml) | Sortillin blood concentration | 1 month | 
| Homocystien(umol/L) | Homocystien blood concentration | 1 Month | 
| Troponin.I (ng/ml) | Troponin.I blood concentration | 1 Month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vaspin, visfatin, lipoprotein A, high-sensitivity C-reactive protein, sortilin, homocysteine, troponin I, fetuin A